로딩 중…
지수 로딩 중…
Recursion Pharmaceuticals, Inc.
RXRX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$3.18+6.00%
2026-08-03
Financials
Valuation Metrics
Recursion Pharmaceuticals, Inc.'s Market Cap is $1.69B. At end of 2025 it was $2.15B. Ranked #2200 of 3,111 in US market (top 71%), #867 of 1,445 on NASDAQ (top 60%), #158 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.69B | US#2,200/3,111 Sec#158/269 |
| Revenue | $66M | US#2,845/3,111 Sec#146/269 |
| Net Income | $-560M | US—/3,111 Sec—/269 |
| Total Assets | $1.34B | US#2,310/3,111 Sec#77/269 |
| Net Assets | $1.02B | US#1,769/3,111 Sec#63/269 |
| Value | ||
| P/B | 1.65x | US#883/3,111 Sec#41/269 |
| P/S | 25.46x | US#2,839/3,111 Sec#152/269 |
| FCF Yield | -19.31% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -54.62% | US#2,761/3,111 Sec#181/269 |
| ROA | -41.79% | US#2,944/3,111 Sec#198/269 |
| Op. Margin | -882.92% | US#2,920/3,111 Sec#176/269 |
| Revenue Growth | -56.11% | US#2,892/3,111 Sec#163/269 |
| Financial Health | ||
| Debt Ratio | 30.71% | US#345/3,111 Sec#110/269 |
| Total Debt | $72M | US#2,499/3,111 Sec#138/269 |
| FCF | $-326M | US#2,805/3,111 Sec#246/269 |
| Cash | $654M | US#898/3,111 Sec#43/269 |
| Current Ratio | 5.47x | US#432/3,111 Sec#136/269 |
| Performance | ||
| 1Y Return | -44.01% | US#2,955/3,111 Sec#243/269 |
| 1M Return | -16.32% | US#2,801/3,111 Sec#230/269 |
| From 52W High | -55.71% | US#2,887/3,111 Sec#238/269 |
| 1Y MDD | -58.17% | US#2,675/3,111 Sec#210/269 |
| Trading | ||
| Volume | 14,524,083 shares | US#111/3,111 Sec#8/269 |
| Trading Value | $45M | US#1,385/3,111 Sec#86/269 |
| Per Share | ||
| EPS | $-1.22 | US—/3,111 Sec—/269 |
| BPS | $2.15 | US#2,494/3,111 Sec#172/269 |